Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Annovis Bio, Inc. (ANVS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/16/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ANNOVIS BIO, INC."
06/02/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/30/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/17/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/04/2023 8-K Termination of a Material Definitive Agreement, Other Events  Interactive Data
04/03/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "ANNOVIS BIO, INC. Common Stock ATM EQUITY OFFERING SM SALES AGREEMENT",
"MEXICO CITY"
04/03/2023 8-K Quarterly results
Docs: "Publication of Phase 1/2 clinical data in The Journal of Prevention of Alzheimer's Disease"
03/31/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/31/2023 8-K Regulation FD Disclosure  Interactive Data
03/06/2023 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review &nbsp...
02/13/2023 8-K Quarterly results
01/06/2023 8-K Investor presentation
Docs: "Presentation"
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
09/12/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Separation Agreement and General Release, by and between the Company and Jeffrey B. McGroarty"
08/30/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Re:",
"Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer"
08/08/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/08/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/04/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/04/2022 8-K Quarterly results
04/18/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/18/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/02/2022 10-K Annual Report for the period ended December 31, 2021
01/18/2022 5 Maccecchini Maria-Luisa (President and CEO) has filed a Form 5 on Annovis Bio, Inc.
11/26/2021 25 Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities:
11/17/2021 CERT Form CERT - Certification by an exchange approving securities for listing:
11/17/2021 8-A12B Form 8-A12B - Registration of securities [Section 12(b)]:
11/15/2021 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...
Docs: "Annovis Bio Announces Transfer of Listing to the New York Stock Exchange"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy